Overview A Study of SPY072 in Rheumatic Disease Status: RECRUITING Trial end date: 2028-03-31 Target enrollment: Participant gender: Summary This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged 18 years) with rheumatic disease (RD).Phase: PHASE2 Details Lead Sponsor: Spyre Therapeutics, Inc.